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Abstract
Surface-associated proteins play a key role in bacterial physiology and pathogenesis and are the major
targets for vaccine development. Recent advances in defining the proteins associated with, and
protruding out of, bacterial cells to a high level of accuracy are substantially contributing to
accelerating the process of vaccine target identification and development.
Introduction and context
Genomic era and high-throughput technologies repre-
sent a turning point in vaccine discovery. The ability to
sequence whole genomes and produce hundreds of
recombinant proteins rapidly and efficiently has enabled
almost entire bacterial proteomes to be scanned by
in vivo and in vitro assays to identify the few protective
antigens that can be included in vaccine formulations.
The first ‘from-genome-to-vaccine’ approach was pio-
neered by Stephen Johnston and colleagues [1], who
constructed a plasmid library of the whole Mycoplasma
genome and used it with DNA immunization to select
the genes that protect mice against Mycoplasma challenge.
Although the approach was not further pursued because
of the inefficiency of DNA immunization when applied
in high-throughput modalities, it represents a hallmark
in vaccinology in that it has set the basis for subsequent,
more effective strategies. One of these strategies involves
the cloning and expression of a large fraction of the
bacterial protein repertoire and the screening of each
purified recombinant protein in appropriate ‘surrogate
of protection’ assays. This approach was first attempted
by Ling Lissolo and coworkers with uncertain results [2]
but subsequently proved to be extremely effective by
Pizza et al. [3], Maione et al. [4] and Stranger-Jones et al.
[5] for an increasing number of pathogens. Vaccines
developed following this strategy are currently in
advanced clinical studies [6] and close to reaching the
market. A second approach involves the shotgun cloning
of the whole genome of a given pathogen such that
Escherichia coli expression libraries are generated in
which clones express protein domains on their surface.
The expression libraries are then screened with sera
from patients infected by the pathogen of interest and
the identified immunogenic proteins are tested for
their capacity to elicit protective immunity in animal
models [7].
The main limitation of the above technologies is that for
them to be effective, several hundreds of proteins have to
be tested in extremely time-consuming and labor-
intensive protection assays, which usually involve
animal immunization and challenge.
From an inspection of all antibacterial subunit-based
vaccines either on the market or in advanced phases of
development, it emerges that their components fall into
the categories of secretedt o x i n so ra b u n d a n t l y
expressed, surface exposed molecules. Therefore, should
effective methods capable of discriminating these
molecules from the plethora of bacterial components
become available, the development of new vaccines
would be greatly accelerated.
Major recent advances
Today, bioinformatics tools are available to predict
surface proteins in bacteria (see [8] and references
therein). However, in silico analyses are still incapable
of providing solid quantitative information on surface
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development.
Several experimental procedures have been described for
the identification of bacterial surface-associated proteins
(reviewed in [9]). They are generally based on (a)
chemical-physical methods to fractionate the different
cellular compartments, (b) separation of membrane-
and cell-wall-enriched fractions by gel electrophoresis or
chromatography, and (c) mass spectrometry analysis of
resolved fractions for protein identification.
In general, these approaches suffer two major limita-
tions. First, fractionation methods aimed at separating
the membrane fraction from the other cellular compart-
ments are only partially efficient, with the result that
several cytoplasmic proteins usually contaminate the
protein mixture undergoing mass spectrometry analysis.
Second, most of the methods developed do not provide
information on the topological organization of the
proteins associated with, or embedded in, the bacterial
membrane. This information is particularly relevant for
vaccine applications because the protein domains
protruding out of the surface are those involved in the
interaction with the host immune system.
Other methods for surface protein characterization
involve selective biotinylation of whole bacteria with
different biotinylating agents and subsequent mass
spectrometry analysis of labeled proteins [10-14].
Although quite informative, these methods also suffer
from the limitations of being poorly quantitative and
selective.
Recently, two strategies have been proposed that at least
partially overcome the above mentioned limitations. The
first of these strategies has been designed for surface-
exposed protein identification in Gram-positive bacteria.
It involves the enzymatic ‘shaving’ of the bacterial surface
with proteolytic enzymes under conditions that preserve
the integrity and viability of bacterial cells. After
digestion, the released peptides are separated from the
‘shaved’ bacteria and subjected to mass spectrometry for
protein identification. The approach has been success-
fully applied in surface protein identification of group A
[15,16] and group B Streptococcus [17]. In most cases, the
presence of the proteins on the bacterial surface has been
confirmed by demonstrating that antibodies against the
recombinant forms of the identified proteins bind live
bacteria, as revealed by fluoresence-activated cell sorting
analysis [15]. One key aspect of this approach is that very
little contamination with cytoplasmic proteins occurs;
therefore, the proteins identified by mass spectrometry
are bona fide surface-exposed proteins. In addition, since
only the protruding domains are accessible to proteases,
the proteolytic peptides generated by the enzymatic
treatment belong to the exposed part of the proteins;
their characterization thus provides useful information
on the topological organization of each identified
protein [15,17].
In Gram-negative bacteria, the ‘shaving’ strategy is
difficult to apply because of the relative fragility of the
cells, which tend to die during protease treatment. For
these bacteria a different approach has been recently
developed that exploits their natural propensity to
release outer membrane vesicles (OMVs) [18,19]. If
specific mutations are selected, the amount of released
OMVs – usually too small for practical purposes – can
substantially increase and reach values of several milli-
grams (in protein content) per liter of culture [20,21].
Because of their small size (50-100 nm in diameter),
OMVs can be easily separated from the bacterial cells by
centrifugation or ultrafiltration (or both) and then
subjected to mass spectrometry analysis for protein
identification.
The proteome characterization of OMVs from a Neisseria
meningitidis group B isolate and from a pathogenic E. coli
strain has been reported recently [21,22]. The data show
that OMVs almost exclusively contain outer membrane
proteins and few periplasmic proteins, exactly as
expected considering that they are generated through a
‘budding out’ of the outer membrane [20]. Interestingly,
preliminary data indicate that, in contrast to parent cells,
OMVs can be shaved with proteases without impairing
their integrity, thus allowing topological studies of
surface exposed proteins (Berlanda Scorza, unpublished
data).
With these newly developed methods, accurate maps of
bacterial surfaces describing protein organization in both
topological and quantitative terms will soon be avail-
able. The data already generated show that the number
of exposed membrane proteins expressed to a sufficiently
high level to become the target of protective immune
responses is limited to a few tens. As experimentally
demonstrated, among them are to be found most, if not
all, future vaccines.
Future directions
Two major aspects remain to be addressed in surface
proteome analysis that might have important implica-
tions in future vaccine development. First, it is well
known that, depending on environmental conditions,
bacteria modulate their surface protein organization. So
far, surface proteomes have been characterized only
under specific and often artificial conditions. Therefore,
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disappearance on the bacterial surface will provide
important insights in bacterial physiology and patho-
genesis. Second, it is expected that certain surface-
exposed proteins interact and constitute functional
protein complexes. So far, very little is known about
which protein complexes are formed on the bacterial
surface and this is a field that awaits future investigation.
Abbreviation
OMV, outer membrane vesicle.
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